Silence Therapeutics plc reported a smaller net loss for the three months ended March 31, 2026 as it advanced its RNAi pipeline and absorbed changes in a key collaboration. Revenue from its AstraZeneca alliance was $0.4 million, up from $0.1 million a year earlier.
Research and development costs fell to $9.1 million from $20.8 million, mainly as Phase 3 readiness work for zerlasiran wound down and headcount declined. Net loss narrowed to $15.0 million (loss per share $0.11) from $28.5 million (loss per share $0.20).
Cash, cash equivalents and short-term investments totaled $70.1 million, and the company believes this will fund operations into 2028, though additional capital will be needed for later-stage development. AstraZeneca decided not to develop SLN312 beyond Phase 1, and Silence will regain full global rights while evaluating further clinical plans. Lead asset divesiran is in a fully enrolled Phase 2 PV trial with topline data expected in the third quarter of 2026, and zerlasiran is Phase 3 ready as the company seeks a partner.
Silence Therapeutics plc reported a smaller net loss for the three months ended March 31, 2026 as it advanced its RNAi pipeline and absorbed changes in a key collaboration. Revenue from its AstraZeneca alliance was $0.4 million, up from $0.1 million a year earlier.
Research and development costs fell to $9.1 million from $20.8 million, mainly as Phase 3 readiness work for zerlasiran wound down and headcount declined. Net loss narrowed to $15.0 million (loss per share $0.11) from $28.5 million (loss per share $0.20).
Cash, cash equivalents and short-term investments totaled $70.1 million, and the company believes this will fund operations into 2028, though additional capital will be needed for later-stage development. AstraZeneca decided not to develop SLN312 beyond Phase 1, and Silence will regain full global rights while evaluating further clinical plans. Lead asset divesiran is in a fully enrolled Phase 2 PV trial with topline data expected in the third quarter of 2026, and zerlasiran is Phase 3 ready as the company seeks a partner.
Silence Therapeutics plc reported first quarter 2026 results, showing higher collaboration revenue and a much narrower loss as it advances its siRNA pipeline. Collaboration revenue from AstraZeneca rose to $0.4 million from $0.1 million a year earlier.
Research and development expenses fell to $9.1 million from $20.8 million, largely after completing zerlasiran Phase 3 readiness in 2025. Net loss improved to $15.0 million, or $0.11 per share, compared with a $28.5 million loss, or $0.20 per share, in the prior-year quarter. The company held $70.1 million in cash, cash equivalents and short-term investments as of March 31, 2026, and its Phase 2 SANRECO trial of divesiran in polycythemia vera remains on track for topline results in August 2026.
Silence Therapeutics plc reported first quarter 2026 results, showing higher collaboration revenue and a much narrower loss as it advances its siRNA pipeline. Collaboration revenue from AstraZeneca rose to $0.4 million from $0.1 million a year earlier.
Research and development expenses fell to $9.1 million from $20.8 million, largely after completing zerlasiran Phase 3 readiness in 2025. Net loss improved to $15.0 million, or $0.11 per share, compared with a $28.5 million loss, or $0.20 per share, in the prior-year quarter. The company held $70.1 million in cash, cash equivalents and short-term investments as of March 31, 2026, and its Phase 2 SANRECO trial of divesiran in polycythemia vera remains on track for topline results in August 2026.
Silence Therapeutics plc has released proxy materials for its 2026 Annual General Meeting, a hybrid meeting on June 16, 2026 in Hoboken, NJ and online. Shareholders will vote on nine ordinary resolutions, including re-appointing directors Rhonda Hellums and James Ede-Golightly, an advisory say-on-pay, and multiple auditor items involving PricewaterhouseCoopers LLP.
Other proposals cover receiving and adopting the 2025 U.K. Annual Report, approving the U.K. statutory directors’ annual report on remuneration, and continuing takeover protections in Article 159 of the articles of association. Ordinary resolutions pass with a simple majority of votes cast. There were 141,703,839 ordinary shares issued and outstanding as of April 24, 2026.
Silence Therapeutics plc has released proxy materials for its 2026 Annual General Meeting, a hybrid meeting on June 16, 2026 in Hoboken, NJ and online. Shareholders will vote on nine ordinary resolutions, including re-appointing directors Rhonda Hellums and James Ede-Golightly, an advisory say-on-pay, and multiple auditor items involving PricewaterhouseCoopers LLP.
Other proposals cover receiving and adopting the 2025 U.K. Annual Report, approving the U.K. statutory directors’ annual report on remuneration, and continuing takeover protections in Article 159 of the articles of association. Ordinary resolutions pass with a simple majority of votes cast. There were 141,703,839 ordinary shares issued and outstanding as of April 24, 2026.
Silence Therapeutics plc is a UK-based biotechnology company developing short interfering RNA (siRNA) medicines using its mRNAi GOLD™ liver-targeted platform. Its lead rare disease program, divesiran (SLN124), is in a fully enrolled Phase 2 SANRECO trial for polycythemia vera, with topline results expected in the third quarter of 2026.
Cardiometabolic pipeline assets include zerlasiran (SLN360), a Phase 3–ready siRNA targeting Lp(a) for cardiovascular disease, SLN312 targeting ANGPTL3, SLN365 for cholesterol via GPR146, and SLN098 for obesity via INHBE, all designed for potent, infrequent subcutaneous dosing. The company believes existing cash, cash equivalents and anticipated milestone payments from current collaborations can fund operations into 2028.
Silence has collaboration histories with AstraZeneca and Hansoh. AstraZeneca advanced SLN312 into Phase 1 with multiple milestone payments but decided on March 4, 2026 not to pursue development beyond Phase 1, after which Silence will regain full global rights. Hansoh paid upfront and milestone amounts on three siRNA targets but elected in December 2024 not to continue development, leaving Silence with worldwide rights to those programs.
Silence Therapeutics plc is a UK-based biotechnology company developing short interfering RNA (siRNA) medicines using its mRNAi GOLD™ liver-targeted platform. Its lead rare disease program, divesiran (SLN124), is in a fully enrolled Phase 2 SANRECO trial for polycythemia vera, with topline results expected in the third quarter of 2026.
Cardiometabolic pipeline assets include zerlasiran (SLN360), a Phase 3–ready siRNA targeting Lp(a) for cardiovascular disease, SLN312 targeting ANGPTL3, SLN365 for cholesterol via GPR146, and SLN098 for obesity via INHBE, all designed for potent, infrequent subcutaneous dosing. The company believes existing cash, cash equivalents and anticipated milestone payments from current collaborations can fund operations into 2028.
Silence has collaboration histories with AstraZeneca and Hansoh. AstraZeneca advanced SLN312 into Phase 1 with multiple milestone payments but decided on March 4, 2026 not to pursue development beyond Phase 1, after which Silence will regain full global rights. Hansoh paid upfront and milestone amounts on three siRNA targets but elected in December 2024 not to continue development, leaving Silence with worldwide rights to those programs.
Silence Therapeutics reported a larger full-year 2025 net loss while highlighting progress across its siRNA pipeline. Collaboration revenue dropped to $0.6M from $43.3M, driving a wider net loss of $88.6M, or $0.63 per share, versus a $45.3M loss in 2024.
Cash, cash equivalents and short-term investments totaled $85.1M as of December 31, 2025. The company emphasized divesiran for polycythemia vera, with the Phase 2 SANRECO trial fully enrolled and topline results expected in 3Q 2026, and completed core Phase 3 readiness work for zerlasiran in high Lp(a).
AstraZeneca completed a Phase 1 interim analysis of SLN312 in dyslipidemia and then decided not to pursue development beyond Phase 1, after which Silence will regain exclusive global rights. Silence also advanced new preclinical programs SLN365 and SLN098 and noted leadership changes with Iain Ross serving as Interim Principal Executive Officer.
Silence Therapeutics reported a larger full-year 2025 net loss while highlighting progress across its siRNA pipeline. Collaboration revenue dropped to $0.6M from $43.3M, driving a wider net loss of $88.6M, or $0.63 per share, versus a $45.3M loss in 2024.
Cash, cash equivalents and short-term investments totaled $85.1M as of December 31, 2025. The company emphasized divesiran for polycythemia vera, with the Phase 2 SANRECO trial fully enrolled and topline results expected in 3Q 2026, and completed core Phase 3 readiness work for zerlasiran in high Lp(a).
AstraZeneca completed a Phase 1 interim analysis of SLN312 in dyslipidemia and then decided not to pursue development beyond Phase 1, after which Silence will regain exclusive global rights. Silence also advanced new preclinical programs SLN365 and SLN098 and noted leadership changes with Iain Ross serving as Interim Principal Executive Officer.
Silence Therapeutics plc’s 10% owner reported internal ADS transfers with no net change in economic exposure. On August 3, 2025, Ora Capital Limited sold 20,000 American Depositary Shares (ADS) at $5.45 per ADS while Richard Ian Griffiths purchased the same amount. On October 27, 2025, OCL sold a further 2,000 ADS at $7.75 per ADS, again matched by Griffiths buying 2,000 ADS. The filing states these are essentially internal transfers with no change in total beneficial holding, and that each ADS is convertible into three ordinary shares for no consideration.
Silence Therapeutics plc’s 10% owner reported internal ADS transfers with no net change in economic exposure. On August 3, 2025, Ora Capital Limited sold 20,000 American Depositary Shares (ADS) at $5.45 per ADS while Richard Ian Griffiths purchased the same amount. On October 27, 2025, OCL sold a further 2,000 ADS at $7.75 per ADS, again matched by Griffiths buying 2,000 ADS. The filing states these are essentially internal transfers with no change in total beneficial holding, and that each ADS is convertible into three ordinary shares for no consideration.
Lombard Odier Asset Management (USA) Corp reports beneficial ownership of 5,935,955 ordinary shares of Silence Therapeutics plc, representing 4.2% of the company. This holding includes 1,978,650 American Depositary Shares, each representing three ordinary shares.
The ownership percentage is calculated using 141,701,848 ordinary shares issued and outstanding as of October 30, 2025. All voting and dispositive power over these shares is shared, with no sole voting or dispositive authority reported.
Lombard Odier Asset Management (USA) Corp reports beneficial ownership of 5,935,955 ordinary shares of Silence Therapeutics plc, representing 4.2% of the company. This holding includes 1,978,650 American Depositary Shares, each representing three ordinary shares.
The ownership percentage is calculated using 141,701,848 ordinary shares issued and outstanding as of October 30, 2025. All voting and dispositive power over these shares is shared, with no sole voting or dispositive authority reported.